C Jackisch

Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.

Andreas du Bois, H.-J. Lück, Werner Meier et al. · PubMed · 1997 · 58 citations

Medicine, Gynecology, Oncology +12

Abstract S5-2: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up

A. Goldhirsch, M.J. Piccart-Gebhart, Marion Procter et al. · Cancer Research · 2012 · 46 citations

Medicine, Oncology, Immuno-oncology Pharmacotherapy +14

S3-2: Neoadjuvant Chemotherapy Adapted by Interim Response Improves Overall Survival of Primary Breast Cancer Patients – Results of the GeparTrio Trial.

G von Minckwitz, Serban Dan Costa, Carsten Denkert et al. · Cancer Research · 2011 · 42 citations

Medicine, Oncology, Breast Oncology +16

Abstract S3-1: Lapatinib vs Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO STUDY (GBG 44)

Michael Untch, Sibylle Loibl, Joachim Bischoff et al. · Cancer Research · 2010 · 38 citations

Medicine, Oncology, Pharmacology +17

The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.

Serban Dan Costa, G von Minckwitz, Günther Raab et al. · PubMed · 1999 · 37 citations

Medicine, Oncology, Pharmacology +13